These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15982353)

  • 1. Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation.
    Cugno M; Agostoni P; Mari D; Meroni PL; Gregorini L; Bussotti M; Anguissola GB; Donatelli F; Nussberger J
    Br J Haematol; 2005 Jul; 130(1):113-20. PubMed ID: 15982353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
    Cugno M; Mari D; Meroni PL; Gronda E; Vicari F; Frigerio M; Coppola R; Bottasso B; Borghi MO; Gregorini L
    Br J Haematol; 2004 Jul; 126(1):85-92. PubMed ID: 15198737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure.
    Chin BS; Langford NJ; Nuttall SL; Gibbs CR; Blann AD; Lip GY
    Eur J Heart Fail; 2003 Mar; 5(2):171-4. PubMed ID: 12644008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between endothelial function and chronotropic incompetence in subjects with chronic heart failure receiving optimal medical therapy.
    Vittorio TJ; Lanier G; Zolty R; Sarswat N; Tseng CH; Colombo PC; Jorde UP
    Echocardiography; 2010 Mar; 27(3):294-9. PubMed ID: 20070352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.
    Farquharson CA; Struthers AD
    J Am Coll Cardiol; 2002 Mar; 39(5):767-75. PubMed ID: 11869839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial function and dysfunction in heart failure.
    Ferrari R; Bachetti T; Agnoletti L; Comini L; Curello S
    Eur Heart J; 1998 Jul; 19 Suppl G():G41-7. PubMed ID: 9717055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
    Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
    Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.
    Hornig B; Arakawa N; Drexler H
    Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term improvement in submaximal exercise capacity by optimized therapy with ACE inhibitors and beta blockers in heart failure patients is associated with restoration of peripheral endothelial function.
    Poelzl G; Frick M; Lackner B; Huegel H; Alber HF; Mair J; Herold M; Schwarzacher SP; Pachinger O; Weidinger F
    Int J Cardiol; 2006 Mar; 108(1):48-54. PubMed ID: 16516697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospects of endothelial dysfunction reversion in patients with congestive heart failure].
    Vizir VA; Berezin AE
    Klin Med (Mosk); 2000; 78(7):36-9. PubMed ID: 10979640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic polymorphisms with endothelial dysfunction in chronic heart failure.
    Kose M; Akpinar TS; Bakkaloglu OK; Tufan A; Sumnu A; Emet S; Kocaaga M; Erk O; Kayacan MS; Güler K; Demirel AS
    Eur Rev Med Pharmacol Sci; 2014; 18(12):1755-61. PubMed ID: 24992619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress.
    Ellis GR; Nightingale AK; Blackman DJ; Anderson RA; Mumford C; Timmins G; Lang D; Jackson SK; Penney MD; Lewis MJ; Frenneaux MP; Morris-Thurgood J
    Eur J Heart Fail; 2002 Mar; 4(2):193-9. PubMed ID: 11959049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Putative contribution of prostaglandin and bradykinin to muscle reflex hyperactivity in patients on Ace-inhibitor therapy for chronic heart failure.
    Scott AC; Wensel R; Davos CH; Georgiadou P; Ceri Davies L; Coats AJ; Francis DP; Piepoli MF
    Eur Heart J; 2004 Oct; 25(20):1806-13. PubMed ID: 15474695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.
    Gibbs CR; Blann AD; Watson RD; Lip GY
    Circulation; 2001 Apr; 103(13):1746-51. PubMed ID: 11282905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide.
    Chong AY; Blann AD; Patel J; Freestone B; Hughes E; Lip GY
    Circulation; 2004 Sep; 110(13):1794-8. PubMed ID: 15364797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radial artery flow-mediated dilatation in heart failure patients: effects of pharmacological and nonpharmacological treatment.
    Giannattasio C; Achilli F; Grappiolo A; Failla M; Meles E; Gentile G; Calchera I; Capra A; Baglivo J; Vincenzi A; Sala L; Mancia G
    Hypertension; 2001 Dec; 38(6):1451-5. PubMed ID: 11751734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: the Frederiksberg heart failure study.
    Chong AY; Freestone B; Lim HS; Kistorp C; Gustafsson F; Hildebrandt P; Lip GY
    Int J Cardiol; 2007 Jun; 119(1):80-2. PubMed ID: 17027106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis.
    Chin BS; Conway DS; Chung NA; Blann AD; Gibbs CR; Lip GY
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):515-21. PubMed ID: 12960603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.